Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Are Priority Review Vouchers The Answer To Incentivize Drug Development? Not So Fast. Pranav Aurora Morgan Romine Gregory Daniel June 15, 2016 10.1377/forefront.20160615.055372 Add to favorites ...

Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...

Priority review, which shortens the standard ten-month FDA review timeline to six months, is typically reserved for drugs that provide a significant improvement in safety or efficacy.

References FDA grants Priority Review to SpringWorks Therapeutics’ New Drug Application for mirdametinib for the treatment of adults and children with NF1-PN. News release. SpringWorks.